Author

Lanie E. Happ

Observed name: Lanie Happ

Observed institutions: Duke University, Duke Cancer Institute

ORCID: 0009-0006-9807-2054

Observed ORCID: 0009-0006-9807-2054

OpenAlex ID: A5029973126

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

2017 · Anupama Reddy, Jenny Zhang, et al. · Cell · 1,121

Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells

2020 · Jennifer Shingleton, Jie Wang, et al. · Cold Spring Harbor Perspectives in Medicine · 25

The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways

2021 · Marco Magistri, Lanie E. Happ, et al. · Cancer Research Communications · 18

Injury promotes sarcoma development in a genetically and temporally restricted manner

2018 · David Van Mater, Eric Xu, et al. · JCI Insight · 14

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

2021 · Brian T. Hill, Caroline J Roth, et al. · Blood · 13

Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy: Report from the 2021 SH/EAHP Workshop

2023 · John R Goodlad, Wenbin Xiao, et al. · American Journal of Clinical Pathology · 11

Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop

2023 · Amy S Duffield, Ahmet Dogan, et al. · American Journal of Clinical Pathology · 9

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

2018 · Nicholas Davis, Matthew S. McKinney, et al. · Blood · 3

Clinical Validation of Duoseq, a Novel Assay for Clinical DNA and RNA Sequencing

2025 · Elizabeth Thacker, Lanie Happ, et al. · Journal of Molecular Diagnostics · 2

Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma

2022 · Jianli Zhou, Aditya Kulkarni, et al. · Blood · 2

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

2022 · Jennifer R Chapman-Fredricks, Devang Thakkar, et al. · Blood · 2

Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study

2026 · Leonardo P.A. Biral, Veronica Russell, et al. · EBioMedicine · 1

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

2024 · Devang Thakkar, Brian T. Hill, et al. · Blood · 1

Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.

2022 · Chrissie Rozzi, Stacey O'Neill, et al. · Journal of Clinical Oncology · 1

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

2021 · Sandeep S. Dave, Lanie Happ, et al. · Blood · 1

Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa

2017 · Jenny Zhang, Anupama Reddy, et al. · Blood · 1

Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation

2026 · Rebecca J. Leeman-Neill, Leonardo P.A. Biral, et al. · Cancer Research Communications

Data from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Supplementary Figure S4 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Figure 3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Supplementary Figure S2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Supplementary Figure S3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Table 1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Supplementary Figure S1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Figure 2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

2026 · Sheren Younes, Fadzai Chinyengetere, et al.

Works count: 51

Citation count: 1,225

H-index: 7

I10-index: 6